Table 8 Comparison of TP53 mutations and clinicopathologic features
From: Prognostic role of serum p53 antibodies in lung cancer
| Ā | No. of cases | No. of patients with TP53 mutations |
|---|---|---|
Age (years) | Ā | Ā |
ā¤60 | 12 | 4 (33.3%) |
>60 | 53 | 12 (22.7%) |
Total | 65 | 16 (24.6%) |
Sex | Ā | Ā |
Male | 51 | 12 (23.5%) |
Female | 14 | 4 (28.6%) |
Total | 65 | 16 (24.6%) |
Histologic type | Ā | Ā |
NSCLC | Ā | Ā |
Adenocarcinoma | 27 | 6 (22.2%) |
Squamous cell carcinoma | 27 | 8 (29.6%) |
Bronchioloalveolar carcinoma | 2 | 0 (0%) |
Large cell carcinoma | 4 | 1 (25.0%) |
Anaplastic carcinoma | 2 | 1 (50.0%) |
Mixed carcinoma | 2 | 0 (0%) |
SCLC | 1 | 0 (0%) |
Total | 65 | 16 (24.6%) |
NSCLC stage | Ā | Ā |
I | 41 | 10 (24.4%) |
II | 9 | 6 (66.7%) |
III | 10 | 0 (0%) |
IV | 4 | 0 (0%) |
Total | 64 | 16 (25.0%) |
NSCLC grade | Ā | Ā |
G1-G2 | 28 | 5 (17.9%) |
G3 | 35 | 11 (31.4%) |
Missing | 1 | 0 (0%) |
Total | 64 | 16 (25.0%) |